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Abstract
The peripheral nociceptor is an important target of pain therapy because many pathological conditions such as
inflammation excite and sensitize peripheral nociceptors. Numerous ion channels and receptors for inflammatory
mediators were identified in nociceptors that are involved in neuronal excitation and sensitization, and new
targets, beyond prostaglandins and cytokines, emerged for pain therapy. This review addresses mechanisms of
nociception and focuses on molecules that are currently favored as new targets in drug development or that are
already targeted by new compounds at the stage of clinical trials - namely the transient receptor potential V1
receptor, nerve growth factor, and voltage-gated sodium channels - or both.
Introduction
Pain research substantially amplifies our understanding of
the nature and mechanisms of pain, and this area is still
expanding. We have learned that different forms of pain
can be distinguished according to their pathogenesis (for
example, nociceptive versus neuropathic pain) (see the
following section), and we are beginning to decipher the
molecular mechanisms involved in different types of pain.
Importantly, this research provided new targets for pain
treatment, and different classes of compounds that are
effective against pain in animal models and that are now
being tested in humans in different phases of clinical
trials have emerged. The two main challenges are the effi-
cacy(are the new drugs better than the old ones?) and the
side effects (are they less dangerous than the old ones?).
The need for better treatment of pain is evident because
worldwide about 20% of adults suffer from chronic pain
[1,2]. In these patients, the current pain therapy is either
not applicable for different reasons (for example, side
effects) or not sufficient [1]. In this review, the focus will
be on molecular targets which are currently favored in
drug development and for which respective compounds
are at different stages of clinical trials.
The nature of pain
It is important to note that pain has different facets. In
normal tissue, pain is elicited by high-energy stimuli
that potentially or actually damage the tissue (noxious
stimuli). This ‘physiological nociceptive pain’ is a warn-
ing sensation and absolutely essential for survival
because it triggers adequate avoidance reactions. Pain
treatment must not impair this type of pain. On the
other hand, pain is an important symptom of disease,
and this pain has to be treated because it impairs nor-
mal life [1]. The pain elicited by inflammation or injury
of an organ is called ‘pathophysiological nociceptive
pain’. This pain is typically elicited by low-energy stimuli
that are normally innocuous and not painful. It appears
as allodynia (occurrence of pain upon an innocuous sti-
mulus) or hyperalgesia (more pain during the applica-
tion of noxious stimuli) or both, and resting pain (in the
absence of any intentional stimulation) may also occur.
Pathophysiological nociceptive pain results from the
sensitization of the pain system (see the following sec-
tion), and the interference with the mechanisms of sen-
sitization provides the opportunity of treatment without
eliminating the physiological nociceptive pain [2,3].
Initially, this pain is beneficial because it indicates the
presence of disease and triggers measures for the sup-
port of healing (cancer is so dangerous because it does
not cause pain in its early stage). However, chronic pain,
in particular, creates severe suffering [1].
Whereas ‘nociceptive pain’ results from noxious stimu-
lation or inflammation/injury of tissue, ‘neuropathic pain’
is evoked by damage to the neurons of the nociceptive
system themselves. Causes include nerve damage, meta-
bolic diseases (for example, diabetes mellitus), and herpes
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noxious tissue stimulation, often feels abnormal (burning
or electrical character), and can be persistent or occur in
short episodes (for example, trigeminal neuralgia). It may
be combined with hyperalgesia and allodynia or with
sensory loss [2,3]. This pain requires treatment that is,
however, often not sufficient. Its mechanisms differ in
part from those of nociceptive pain.
Neurophysiology of peripheral nociceptors in
health and disease
Noxious stimuli are detected by nociceptors that are
present in almost all organs. These specialized sensory
neurons have Aδ- and C-fibers in the peripheral nerve
and sensory non-corpuscular ‘free nerve endings’ in the
innervated organs. Most nociceptors are polymodal,
responding to noxious mechanical stimuli (painful pres-
sure, squeezing the tissue), noxious thermal stimuli
(heat or cold), and noxious chemical stimuli. They are
equipped with sensor molecules in the sensory endings
which transduce these mechanical, thermal, and chemi-
cal stimuli into a depolarizing sensor potential [2-5]
(Figure 1). When this depolarization is sufficiently large,
it opens voltage-gated Na
+ channels and triggers the
generation of action potentials that are conducted to the
dorsal horn of the spinal cord or the brainstem (Figure
1). From their sensory endings, the peptidergic nocicep-
tors can release the neuropeptides substance P and cal-
citonin gene-related peptide (CGRP), which induce
vasodilatation, plasma extravasation, and other effects,
thus producing a ‘neurogenic inflammation’ [6].
Inflammation sensitizes polymodal nociceptors. Their
excitation threshold drops such that even light, normally
innocuous stimuli activate the fibers, and noxious sti-
muli evoke stronger responses than in the non-sensi-
tized state. In addition, inflammation recruits so-called
silent nociceptors for activation [2,3,7]. These C-fibers
are inexcitable by noxious mechanical or thermal stimuli
in normal tissue but inflammation sensitizes them to
become responsive to stimuli. This ‘peripheral sensitiza-
tion’ induces a hyper-excitability of nociceptive neurons
in the central nervous system (’central sensitization’),
and the two together generate the features of pathophy-
siological nociceptive pain, namely allodynia and hyper-
algesia [2,8,9]. Peripheral sensitization is induced by
inflammatory mediators that change the response prop-
erties of ion channels through the activation of second
messenger systems (Figure 1).
The pathophysiology of neuropathic pain is different.
While in healthy sensory nerve fibers action potentials
are generated in the sensory endings upon stimulation
of the receptive field, damaged nerve fi bers (including
non-nociceptive Ab-fibers [10]) often show pathological
ectopic discharges that are generated at the site of nerve
injury or in the cell body in dorsal root ganglia (DRGs)
[3,11]. Neuropathic pain may also be generated by intact
nerve fibers in the vicinity of injured nerve fibers [12].
Ectopic discharges are thought to be produced by
changes in the expression of ion channels [13], patholo-
gical activation of axons by inflammatory mediators
[14], and pathological activation of injured nerve fibers
by the sympathetic nervous system [15].
However, the question of whether there is always a
strict distinction between these types of pain under clin-
ical conditions arises. For example, osteoarthritic pain is
considered mainly a pathophysiological nociceptive pain
because the joints may show severe damage and inflam-
mation [16]. However, changes that are typical for neu-
ropathic conditions may occur in the nervous system
[17]. Possibly, pain types become less discernible with
time.
Another emerging aspect of pain is that significant
differences between the nociceptive innervation and pro-
cesses in different tissues exist. First, the skin is inner-
vated by two large populations of nociceptors, namely
peptidergic (containing substance P and CGRP) and
non-peptidergic IB4 (isolectin B4)-positive nociceptive
aerents [2,5], whereas the vast majority of aerents in the
musculoskeletal system are peptidergic [18,19]. Second,
nociceptors in skin and musculoskeletal system have
relatively high mechanical thresholds that clearly distin-
guish them from non-nociceptive low-threshold sensory
fibers [20,21], whereas most putative nociceptors in the
viscera have their excitation threshold in the innocuous
range [22]. Third, during inflammation, nociceptors in
the muscle and joint are strongly sensitized to mechani-
cal stimuli whereas cutaneous nociceptors are rather
sensitized to thermal stimuli [20,21,23]. These differ-
ences, often ignored, may have a significant impact on
drug development. Although there is an overlap of noci-
ceptive mechanisms in different tissues, the awareness
of tissue-specific nociceptive mechanisms may become
more important in the future [2]. Notably, most chronic
pain occurs during diseases of the musculoskeletal
system whereas skin diseases are rarely painful [1].
Principles of molecular mechanisms of
nociception and sensitization
The identification of these mechanisms is based on dif-
ferent experimental approaches. Electrophysiological and
behavioral experiments in the intact organism are used
to study nociceptive processes in situ. However, the sen-
sory free nerve endings themselves cannot be accessed
in situ for recordings, because they are extremely small
and embedded in the tissue. Fortunately, the more
accessible somata of the nociceptors in the DRGs also
express the relevant molecules. Therefore, patch clamp
recordings are usually carried out in cultured DRG
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body and the endings in the tissue might exist [23]. Pain
research aims to achieve convergent information from
behavioral experiments in vivo (for example, in wild-
type and knockout animals), invasive experiments in
situ, and experiments in cultured neurons.
As mentioned, the excitation of nociceptor endings is
produced by ion channels in the membrane which open
upon the impact of physical stimuli to the membrane. The
cation influx through these channels produces a local
depolarization, the sensor potential. Once the ending is
sufficiently depolarized by the influx of cations, voltage-
gated Na
+ channels are opened and action potentials are
triggered (Figure 1). K
+ and Ca
2+ channels control excit-
ability of the neurons. During the process of sensitization,
the gating properties of ion channels are modified by
inflammatory mediators that act on metabotropic mem-
brane receptors and activate second messenger systems
[24]. Inflammatory mediators may also evoke neuropathic
ectopic discharges [25]. Depending on the mediator, the
sensitization of nociceptors can be induced within minutes
(for example, by phosphorylation of ion channels in the
membrane) or hours [23,26,27]. In the long term, the
expression of receptors and ion channels may be regulated
such that more molecules are available for stimulation [2].
These changes may be induced by inflammatory mediators
such as cytokines [28,29] and nerve growth factor (NGF)
[30]. The following paragraphs address ion channels and
receptors that were and are a major focus of pain research
and some of them are the focus of drug development.
The TRPV1 receptor
A lot of effort is put into the development of antago-
nists against the transient receptor potential V1
(TRPV1) receptor, and it is hoped that these antagonists
become new analgesics. In fact, clinical trials are under
way. Why is there so much interest in the TRPV1
receptor? In the last 10 to 15 years, the TRPV1 receptor
was one of the hot topics in pain research and is now
considered one of the key molecules in nociception
[2,5]. The TRPV1 receptor is a ligand-gated ion channel.
Upon opening, cations (in particular, Ca
2+) flow into the
cell and depolarize it. Importantly, the TRPV1 receptor
is expressed in nociceptors but not in other peripheral
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Figure 1 Schematic drawing of a sensory ending of a nociceptor in the tissue. The membrane at the bottom shows ion channels for
transduction (which produce a sensor potential, SP), a voltage-gated Na
+ channel for the generation of action potentials (APs), and voltage-
gated K
+ and Ca
2+ channels that control excitability. The other part of the membrane displays receptors for mediators that act on different
second messenger systems. Classical inflammatory mediators are bradykinin, prostaglandin E2, 5-hydroxytryptamine, and histamine. ASIC, acid-
sensing ion channel; PTX, purinergic ion channel; TRP, transient receptor potential.
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nociceptive neurons and not on other ones. Stimuli that
open the TRPV1 receptor are manifold. First, it is
opened by temperatures of higher than 43°C, which are
felt as painful heat by humans. TRPV1-deficient mice
show attenuated responses to heat stimuli [5] but other
molecules seem to contribute to noxious heat sensations
as well [23]. Second, TRPV1 is opened by chemicals
(such as capsaicin and ethanol applied to a wound) that
elicit burning pain [30,31]. However, the main interest
for analgesic therapy comes from the findings that the
channel characteristics are modified by metabolites that
occur in inflamed tissue. In fact, the TRPV1 is opened
by low pH (<5.9) occurring in inflamed tissue and is
activated by arachidonic acid metabolites produced by
lipoxygenases such as 12-hydroperoxyeicosaenoic acid
(12-HPETE) and by endocannabinoids such as anan-
damide and NADA (N-arachidonyl-dopamine) [30].
Further-more, TRPV1 is indirectly sensitized, via second
messengers, by the inflammatory mediators bradykinin,
prosta-glandin E2, extracellular ATP, glutamate, pro-
teases, and NGF [25,27,30,31]. Cellularly, sensitization
may be produced by the increase of TRPV1 expression
level in the membrane, the phosphorylation by protein
kinases, and the release of inhibition of TRPV1 by phos-
phatidyl-inositol-4,5-biphosphate [25]. The important
consequence of this sensitization is that the threshold
for opening by temperature stimuli drops such that
normal body temperature may be sufficient to activate
nociceptors and to elicit action potentials. This form
of hyperalgesia is tested by thermal stimuli; in fact,
TRPV1-deficient mice do not show the typical inflam-
mation-evoked thermal hyperalgesia in acute carragee-
nan- or complete Freund’s adjuvant (CFA)-induced
inflammation [30,31].
However, there are some caveats that may limit the
success of TRPV1 antagonists. First, in humans, inflam-
matory pain appears mainly as mechanical hyperalgesia
(that is, the sensitization of the nociceptive system
toward mechanical stimulation) [2,3]. The initial data
showed that TRPV1-deficient mice exhibit normal
responses to noxious mechanical stimuli and that
inflammation-evoked mechanical hypersensitivity is not
reduced [31]. Thus, TRPV1 was classified as a key mole-
cule for thermal hyperalgesia but not for mechanical
hyperalgesia [25]. Only recently, an involvement of
TRPV1 in mechanical hyperalgesia was reported in adju-
vant-induced chronic arthritis [32]. It is still unclear,
therefore, whether TRPV1 receptor antagonists will be
efficient against significant mechanical hyperalgesia (for
example, during osteoarthritis). Second, the role of
TRPV1 receptors in neuropathic pain is not well under-
stood. While it was proposed that TRPV1 receptors are
important in the generation of chemical and thermal
hyperalgesia in neuropathy, even a protective role of
TRPV1 against the development of mechanical hyperal-
gesia was observed [31]. Thus, the presence of a neuro-
pathic pain component could spoil the success of
TRPV1 receptor antagonists.
Other TRPV receptors
Sensory neurons also express other TRP receptors that
can be colocalized with TRPV1. The functional signifi-
cance of other TRPV receptors is much more uncertain
or even confusing. Therefore, they are currently not
considered targets for antinociceptive therapy, although
they might be involved in aspects of nociception [25,31].
The TRPV2 receptor is activated by high temperature
(threshold of about 52°C) and may be the heat sensor in
high-threshold-temperature Aδ nociceptors. TRPV2 and
TRPV1 are colocalized in a very small percentage of
DRG neurons [31]. TRPV3 is activated by innocuous
temperature stimuli in the range of 31°C to 39°C but
shows increased responses to noxious thermal stimuli
and may contribute to pain hypersensitivity during
inflammation. It can be colocalized with the TRPV1
receptor [31]. TRPV4 is activated by innocuous warmth
with a threshold of greater than 27°C. Some data sug-
gest that TRPV4 may, in fact, play a role in the trans-
duction of mechanical stimuli and in mechanical
hyperalgesia following exposure to inflammatory media-
tors [5]. The transient receptor potential A1 (TRPA1)
was initially considered the transduction molecule for
noxious cold stimuli because its activation threshold is
below 18°C [31] (this skin temperature may feel painful),
but there is no consensus whether TRPA1 is really a
noxious cold sensor [5,33]. The transient receptor
potential M8 (TRPM8) receptor is activated in the range
of 23°C to 28°C and is also activated by cooling com-
pounds such as menthol, eucalyptol, and icilin [31]. It is
assumed that this particular TRP receptor might be the
receptor for the sensation ‘cool’ (not painful) in non-noci-
ceptive nerve fibers; in fact, TRPM8 is rarely colocalized
with the other TRP receptors.
The involvement of other TRP receptors in nocicep-
tion is suggested by their sensitivity to irritant mediators
or mediators involved in inflammation or by the fact
that they are upregulated under inflammatory conditions
or by both. TRPV2 is upregulated in DRG neurons after
intra-plantar injection of CFA [31]. TRPV3 shows
responses to camphor and other irritants, nitric oxide
(NO), and arachidonic acid and other fatty acids [31].
TRPV4 is activated by phorbolester, low pH, citrate,
endocannabinoids, arachidonic acid metabolites, and
NO [31]. TRPA1 is activated by bradykinin and by pun-
gent ingredients of mustard oil, garlic, and others, all of
which induce an acute painful burning or pricking
sensation [31].
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fined to peripheral sensory neurons. They are also
detected in the central nervous system and even in non-
neuronal tissue. For example, TRPV4 is expressed in
cochlear hair cells, and both TRPV3 and TRPV4 are
expressed in keratinocytes [30,31]. Whether this restricts
or prevents the usage of TRP antagonists as analgesic
remains to be seen.
Acid-sensing ion channels
Acid-sensing ion channels (ASICs) are members of the
ENa/degenerin family of highly selective Na
+ channels.
They are expressed in numerous DRG neurons [5].
ASICs are activated by low extracellular pH and thus
are important sensors of tissue acidosis, which often
occurs during inflammation. Several isoforms of ASICs
were reported [25]. Perhaps ASICs are most important
in the skeletal muscle and heart, in which impaired cir-
culation causes immediate pain [5,34].
ATP and purinergic ion channels
In some tissues, extracellular ATP is thought to act as a
pain mediator. ATP opens purinergic receptors (P2X2
and P2X3) which are ligand-gated Ca
2+ channels. ATP
can be released from damaged cells or from keratino-
cytes of the inflamed skin [25]. Like protons, ATP may
be particularly important in contracting muscles [34].
The Ca
2+ influx depolarizes cells and causes secondary
Ca
2+ influx through voltage-gated Ca
2+ channels. P2X
activation was implicated in the development of inflam-
matory hyperalgesia [25].
Voltage-gated Na
+ channels and other voltage-
gated ion channels
Voltage-gated Na
+ channels are essential for the genera-
tion and conductance of action potentials. The analgesic
effect of local anesthetics is due to their ability to block
voltage-gated Na
+ channels and thus to prevent the con-
duction of action potentials. Because local anesthetics
block Na
+ channels in all nerve fibers (including moto-
neurons, touch receptors, and thermoreceptors), their
long-term use for pain treatment is not feasible. How-
ever, recent research revealed that different types of Na
+
channels exist and that some of them are particularly
expressed in nociceptive neurons. Therefore, a lot of
effort is put into research on Na
+ channels and their
putative utilization for pain treatment.
Nociceptive neurons express mainly Nav1.7, Nav1.8,
and Nav1.9, whereas large-sized non-nociceptive DRG
neurons express mainly Nav1.1, Nav1.6, and Nav1.7 and
some Nav1.8 [2,35]. Nav1.1, Nav1.6, and Nav1.7 can be
blocked by tetrodotoxin (TTX) and are called TTX-sen-
sitive (TTX-S), whereas Nav1.8 and Nav1.9 are TTX-
resistant (TTX-R). Na
+ influx into the neuron through
TTX-S Na
+ channels activates and inactivates very
quickly, and Na
+ influx through TTX-R Na
+ channels
activates and inactivates more slowly. Most likely, con-
duction of action potentials in the axons of primary
afferents rests mainly on TTX-S Na
+ channels, whereas
TTX-R Na
+ currents are important in the action poten-
tial generation in the sensory endings and the cell
bodies [36]. The channels are up- or downregulated by
second messenger pathways involving protein kinase A,
protein kinase C, sphingomyelinase, calmodulin, and
p38 mitogen-activated protein kinase [13].
The resting potential of DRG neurons is about -60 mV.
Nav1.7 opens after small depolarizations (at -50 to -40
mV), and this initial Na
+ influx brings the neuron closer
to the membrane potential for elicitation of an action
potential [35]. Nav1.8, which is expressed only in sensory
neurons and largely restricted to nociceptive neurons,
opens at -30 to -20 mV - that is, when the cell has been
pre-depolarized (for example, by Nav1.7) - and provides
about 80% of the inward current of the upstroke of the
action potentials in DRG neurons. In particular, this Na
+
channel is targeted primarily to terminals and the cell
body, suggesting a role in action potential initiation at
the sensory terminal of nociceptors [13]. It also mediates
repetitive action potentials during persistent membrane
depolarization (for example, in the presence of inflamma-
tory mediators) [35]. While Nav1.7 and Nav1.8 are
directly involved in the generation of the action potential,
Nav1.9 influences the threshold for action potentials. The
channel opens around -60 mV and conducts persistent
Na
+ currents at subthreshold voltages for action potential
firing and thus regulates the distance between membrane
potential and threshold; it does not contribute to the
upstroke of the action potential [35].
The critical importance of these Na
+ channels in noci-
ception is obvious from numerous findings. A gain-of-
function mutation and a loss-of-function mutation of
Nav1.7 channel in humans directly demonstrated the
involvement of Nav1.7 current in pain perception [37].
During inflammation, Nav1.7 channel mRNA and pro-
tein are increased, and in mice with Nav1.7 deletion,
inflammatory hypersensitivity is either absent or drama-
tically attenuated [13]. Nav1.8 current is increased by
proinflammatory mediators such as adenosine, endothe-
lin, NGF, prostaglandin E2, serotonin, and tumor necro-
sis factor-alpha (TNF-a) [13]. Antisense knockdown of
Nav1.8 attenuates the development and maintenance of
inflammatory hyperalgesia and can also prevent and
reverse hypersensitivity observed following traumatic
nerve injury [13]. Nav1.9 is also potentiated by inflam-
matory mediators [25].
The excitability of neurons may also be controlled by
K
+ channels (for example, of the potassium voltage-
gated channel subfamily KQT [KCNQ] family) and Ca
2+
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+
channels are inhibited (this evokes sustained depolariza-
tion of neurons) or when Ca
2+ flows into the neuron
through voltage-gated T-type channels [25].
Mediators activating, sensitizing, and altering
nociceptive neurons
Figure 1 schematically shows receptors for classes of
inflammatory mediators without addressing all media-
tors and receptor subtypes in detail (this is beyond the
scope of this review). It should be noted that not all of
the receptors are located in all neurons. Instead, only
subpopulations of neurons respond to certain mediators,
but the nociceptive system as a whole is responsive to
all of the mediators indicated.
’Classical inflammatory mediators’ such as bradykinin
and prostaglandins [5,27,38] activate or sensitize neu-
rons (or both) within minutes. For example, prostaglan-
din E2 acts on G protein-coupled prostaglandin E
receptors that increase cAMP. This activates protein
kinase A, which finally leads to a phosphorylation of
TRPV1 receptors and voltage-gated Na
+ currents. The
importance of this sensitizing mechanism is underscored
by the ability of prostaglandin synthesis inhibitors to
reduce sensitization. More recent research showed that
cytokines can induce long-lasting effects on the excit-
ability and also produce prolonged effects such as regu-
lation of receptor expression [28,29]. In this context, it
may be important that, in the acute phase of inflamma-
tion, macrophages invade the DRGs of the segments
that innervate the inflamed organ; that is, macrophages
may directly influence the cell bodies [39]. The blockade
of TNF-a signaling was found to reduce inflammatory
hyperalgesia, at least in part by a neuronal target
[28,39,40].
A highly favored target for new drugs is NGF, and
recent clinical studies using an antibody against NGF
entered phase III [41] (with a set back, however, because
the US Food and Drug Administration put a halt to
some studies). Why is NGF a hot target? First, NGF is
an essential growth factor for the development of nor-
mal nociceptors. In the adult, a large proportion of noci-
ceptors remain dependent on the trophic effect of NGF.
These neurons express tyrosine receptor kinase A
(TrkA) receptors (specific receptor for NGF), and NGF
is required for their structural and functional integrity
[42]. Neutralization of NGF may thus disturb the noci-
ceptive function of these neurons. Second, several cell
types produce substantial amounts of NGF at inflamma-
tory sites, and NGF can directly affect neurons. NGF
enhances currents through TRPV1 channels and reduces
the threshold of thermal excitation [30]. In vivo,t h e
application of NGF generates hyperalgesia, and pretreat-
ment with antibodies to NGF or a fusion protein
attached to a modified TrkA receptor attenuates inflam-
mation-induced hypersensitivity. Third, long-term expo-
sure to NGF increases the expression of TRPV1,
bradykinin receptors, P2X receptors, Na
+ channels, and
the synthesis of putative nociceptive transmitters such
as substance P and CGRP [30]. Fourth, NGF stimulates
inflammatory cells to release inflammatory compounds
[30]. Thus, NGF is a key molecule for nociceptor biol-
ogy, and its neutralization proved to be highly analgesic
in humans [41]. It remains to be seen whether NGF
neutralization will become a therapeutical option or
whether NGF neutralization may impair the function of
nociceptors too much.
Mediators with inhibitory actions
The drugs addressed so far reduce excitation/sensitization
by neutralizing pronociceptive mediators and by interfer-
ing with ion channels of nociception. The multitude of
mediators and ion channels involved in the generation of
pain may limit the success of all efforts to treat pain by
interfering with single molecules. Whether neutralization
of NGF as a mediator with ‘integrative functions’ is feasi-
ble will be shown. Another principle of pain treatment is
to employ drugs that stimulate endogenous inhibitory
mechanisms. In fact, sensory neurons exhibit receptors
that mediate inhibition of neuronal activity. Recently, per-
ipheral opioid receptors were shown to produce profound
antinociception experimentally as well as clinically [30].
Further receptors with inhibitory actions are receptors for
somatostatin [43] and cannabinoids [44]. Experimentally,
the use of specific agonists at these receptors produces
antinociception [44-46]. However, the cannabinoid
anandamid also activates TRPV1 receptors that may
counteract antinociception [30,45].
Conclusions
Although peripheral mechanisms of nociception signifi-
cantly contribute to the generation of pain, the contri-
bution of spinal, as well as supraspinal, thalamocortical
mechanisms to pain generation is essential [47,48]. As
mentioned, peripheral sensitization often causes central
sensitization [8,9]. This is even induced by a single
intradermal injection of capsaicin, which activates
TRPV1 receptors [49], and is quite prominent and long-
lasting during persistent inflammation in joints [3,21].
Thus, both peripheral and central nociceptive mechan-
isms are options for the improvement of pain therapy.
Note
This article is part of the series Evolving understanding
of the biology of pain and its application to patient care,
edited by Daniel Clauw and Anthony Jones. Other arti-
cles in this series can be found at http://arthritis-
research.com/series/pain
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